AI Bot Trading has proven to be a successful strategy for generating gains in the stock market, as evidenced by its recent performance with ZOM. In the case of ZOM, the AI bot trading strategy resulted in impressive gains of 10.71%. This notable achievement showcases the potential of artificial intelligence in identifying profitable investment opportunities.
Furthermore, recent market data suggests that ZOM's upward momentum is likely to continue. After experiencing a 5.94% increase over a three-day period, the price of ZOM is estimated to grow further. Historical analysis of similar situations where ZOM recorded three consecutive days of advances reveals that in 185 out of 224 cases, the price continued to rise within the following month. This translates to a promising 83% probability of a continued upward trend.
Investors and traders who are considering ZOM as potential investors should take note of these findings. While past performance is not a guarantee of future results, the consistent historical pattern of price growth following a three-day advance in ZOM suggests a higher likelihood of further gains in the near future.
It is important to remember that AI bot trading strategies are based on analyzing vast amounts of data and patterns that may not be readily apparent to human traders. By leveraging advanced algorithms and machine learning capabilities, these trading systems can identify potential opportunities with higher accuracy and efficiency.
ZOM saw its Momentum Indicator move above the 0 level on June 09, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where ZOM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ZOM just turned positive on June 08, 2023. Looking at past instances where ZOM's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZOM advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .
ZOM moved below its 50-day moving average on May 11, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ZOM broke above its upper Bollinger Band on May 10, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.728) is normal, around the industry mean (42.679). P/E Ratio (0.000) is within average values for comparable stocks, (53.763). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.717). ZOM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (9.276) is also within normal values, averaging (55.932).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ZOM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZOM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company that develops medication for animals
|MFs / NAME||Price $||Chg $||Chg %|
|Nationwide BNY Mellon Dyn US Core R6|
|Goldman Sachs Global Rl Estt Secs A|
|Centre American Select Equity Inv|
|JPMorgan International Equity R5|
|Guggenheim Small Cap Value A|
A.I.dvisor indicates that over the last year, ZOM has been loosely correlated with ACB. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOM jumps, then ACB could also see price increases.
|ACB - ZOM|
|OGI - ZOM|
|SNDL - ZOM|
|CRON - ZOM|
|TLRY - ZOM|